The Ledger

DGX

Quest Diagnostics IncHealth Careinsider_universe

Last close $197.76Jun 16, 2026

Day −1.63%

Currently held

Agent 5 — Dip Buyer (Evolving)long
6 sh @ $187.94 · stop $172.90
+$59.34 unrealized

Everything we've seen

·Jun 18, 4:04 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 4:04 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 4:04 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 3:49 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 3:49 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 3:49 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 3:34 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 3:34 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 3:34 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 3:19 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 3:19 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 3:19 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 3:04 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 3:04 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 3:04 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 2:49 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 2:49 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 2:49 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 2:34 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 2:34 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 2:34 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 2:19 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 2:19 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 2:19 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 2:04 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 2:04 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 2:04 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 1:49 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 1:49 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 1:49 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 1:34 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 1:34 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 1:34 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 1:19 AMstreamnews
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
·Jun 18, 1:19 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 1:19 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
·Jun 18, 1:04 AMstreamnews
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
·Jun 18, 1:04 AMstreamnews
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
?Jun 17, 10:30 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
!Jun 17, 10:30 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
❖Jun 17, 9:00 AMnewsvia finnhub
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 financial results on Thursday, July 23, 2026, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.
❖Jun 16, 9:00 AMnewsvia finnhub
Quest Diagnostics Unveils Achievements in Healthcare Access, Employee Engagement and Environmental Sustainability in 2025 Corporate Responsibility Report
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
❖Jun 16, 8:30 AMnewsvia finnhub
GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth
GAITHERSBURG, Md., June 16, 2026--GeneDx today announced the appointment of Mark Gardner as President, effective June 15, 2026.
❖Jun 12, 5:10 AMnewsvia finnhub
Quest Diagnostics Inc (NYSE:DGX): A Top Dividend Stock with Sustainable Income and Growth Potential
Quest Diagnostics (DGX) offers a 1.75% dividend yield with strong 7.42% annual growth. Featuring a sustainable 35% payout ratio and solid profitability, this stock balances reliable income with financial stability.
!Jun 11, 10:47 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 11, 9:47 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 11, 9:16 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 11, 9:05 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 11, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 6:04 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 5:45 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 5:30 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 5:15 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 5:01 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 4:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 4:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 4:17 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 4:03 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 3:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 2:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 2:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 2:16 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 2:03 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 1:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 1:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 1:16 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 1:05 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 12:46 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 12:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 12:16 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 12:05 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 11:46 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 10, 11:32 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 10, 9:22 AMnewsvia finnhub
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare
Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare are benefiting from telehealth, AI adoption and growing home-care demand.
?Jun 9, 10:42 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 1.80% today with no attributable headline, suggesting this is flow-driven rather than news-driven. At ~1.80% the move is meaningful but not yet at a magnitude that typically signals exhaustion. With 304 minutes remaining (essentially a full afternoon session), there is ample time for continuation. The macro context shows a compressed yield curve (T10Y2Y at 2.0σ below 24-month trend), which tends to benefit defensives like healthcare/lab diagnostics — DGX fits this profile as a defensive, non-cyclical name. This is modestly supportive of the upward move. No reversal signals are evident from the data provided. The absence of news is not disqualifying per framework guidance. Overall this is an ordinary momentum setup with mild macro tailwind, warranting a modest continuation probability above 0.5 but not a high-conviction call.
❖Jun 9, 10:40 AMnewsvia finnhub
4 Outpatient Home Health Stocks Benefiting From Industry Trends
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
?Jun 5, 9:35 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 1.67% today, a moderate but not exceptional intraday move. With 370 minutes remaining (well over 6 hours), there is ample time for the move to continue or extend into the close, which is a mild positive. The macro context shows T10Y2Y at 1.9σ below trend, which is modestly flattening/bear-flattening — this tends to favor defensives like healthcare/lab services names such as DGX, providing a slight tailwind. The only headline is a generic pre-market mover recap with no DGX-specific negative catalyst identified. Absence of a clear reversal catalyst, combined with the defensive sector tilt being supportive in the current macro environment, keeps momentum leaning positive. However, the move is not large enough to signal strong institutional conviction, and the macro read is indirect. No reversal pattern is evident. Overall, a modest continuation probability above the 0.5 threshold is warranted.
❖Jun 5, 8:35 AMnewsvia finnhub
Top S&P500 movers in Friday's pre-market session
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.
❖Jun 4, 1:08 PMnewsvia finnhub
How The Quest Diagnostics (DGX) Investment Story Is Evolving Without New Analyst Price Target Changes
Quest Diagnostics is in focus today as the latest update shows no changes to the current price targets set by covering analysts. Even without fresh commentary driving the story, the lack of adjustment itself can be useful context as you think about how the stock fits into your watchlist or portfolio. Read on to see how to monitor future shifts in the analyst narrative so you can stay on top of what changes and what stays the same. Wall Street's queuing for one rocket. While SpaceX counts down...
❖Jun 4, 11:30 AMnewsvia finnhub
DaVita HealthCare (DVA) Up 0.6% Since Last Earnings Report: Can It Continue?
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
❖Jun 1, 8:09 AMnewsvia finnhub
Encompass Health to Expand WV Footprint With 36-Bed Bridgeport Unit
EHC is expanding its rehabilitation network with a new 36-bed hospital in West Virginia.
❖May 29, 12:00 PMnewsvia finnhub
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know
Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
❖May 28, 1:26 PMnewsvia finnhub
3 Reasons to Sell DGX and 1 Stock to Buy Instead
Since November 2025, Quest has been in a holding pattern, posting a small return of 2.6% while floating around $194.06. The stock also fell short of the S&P 500’s 9.8% gain during that period.
❖May 26, 9:40 AMnewsvia finnhub
Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year?
Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
❖May 25, 8:32 AMnewsvia finnhub
Quest Diagnostics Stock: Analyst Estimates & Ratings
Quest Diagnostics is keeping analysts reasonably upbeat as steady execution and momentum continue supporting Wall Street confidence.
❖May 23, 9:16 AMnewsvia finnhub
1 Profitable Stock to Own for Decades and 2 We Avoid
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
?May 19, 9:05 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is up 1.73% intraday, a modest but real move reflecting genuine buying flow. No news catalyst is present, which is common and not disqualifying. With 400 minutes remaining (well over a full session), there is ample time for continuation. However, the macro context is modestly cautionary: T10YIE is running 2.4σ above trend, suggesting elevated inflation expectations which can pressure defensive/dividend-sensitive healthcare names like DGX at the margin. The move itself is below the 2% threshold that would signal strong conviction, so this is an ordinary momentum read rather than a high-conviction setup. No reversal signals are evident from the data provided. Net assessment: slight edge to continuation given time remaining and the positive flow signal, but macro headwinds cap confidence. Probability sits just above the 0.5 threshold.
?May 18, 9:25 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
Quest Diagnostics is a fundamentally solid business — a recent article highlights strong profitability and financial health, and it carries a reliable dividend. The 11% drop appears to be largely sector-driven, as Health Care (XLV) is ranked 10 of 11 in 30-day relative strength with a -13.87pt sector underperformance vs SPY, suggesting DGX is caught in a broad sector selloff rather than experiencing company-specific deterioration. However, confirmation signals are absent: no insider buying, no unusual call flow (put/call ratio of 8.88 is extremely elevated, indicating heavy put activity), and no SEC filings clarifying the move.
?May 18, 8:54 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a large-cap, defensive healthcare services company with stable recurring revenue from laboratory testing — no recent SEC filings or news headlines suggest fundamental deterioration, so the 11% pullback from the 30-day high appears to reflect broad macro pressure rather than company-specific issues. The elevated 5-year breakeven inflation rate (2.7%, 2.5σ above trend) signals a risk-off rotation into inflation-hedged assets and away from stable-growth defensives, which could explain near-term multiple compression. However, with no confirming catalyst for the drop and DGX's historically resilient earnings profile, a partial mean-reversion toward the prior high over 90 days is plausible but not highly probable given the macro headwind.
❖May 18, 6:20 AMnewsvia finnhub
Quest Diagnostics (NYSE:DGX): A Solid Dividend Play Backed by Strong Profitability and Financial Health
Discover how Quest Diagnostics (DGX) offers a sustainable 1.83% yield with strong profitability and health ratings, avoiding yield traps for reliable dividend growth.
?May 16, 6:35 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $6.08 cash available; close=$186.61.
?May 16, 10:05 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX is down 11% from its 30-day high at $186.61, but the evidence base is almost entirely empty: no recent news headlines, no SEC filings, no insider activity, no options flow, and no upcoming earnings catalyst to anchor a rebound thesis. The macro backdrop is mixed-to-negative for a swing entry: broad market is broadly selling off today (SPY -1.20%, IWM -2.41%), VIX is at the 50th percentile (not extreme fear, so no contrarian capitulation signal), the 10Y yield at 4.47% is near the structural headwind threshold, and 5-year inflation breakevens printing 2.7 (2.5σ above trend) suggest a rates/inflation repricing that could pressure valuation multiples on defensive healthcare names. Without a confirmed sector-wide selloff as the culprit (no sector flow data), the idiosyncratic nature of the drop is unexplained, which increases uncertainty rather than providing a clear dip-buying rationale. The absence of any cluster insider buying removes what would otherwise be the most reliable positive signal for a fundamentals-oriented value trade. Healthcare/diagnostics is a relatively defensive sector, and DGX has reasonable fundamental characteristics generally, but with no confirmatory evidence and a deteriorating near-term macro tone, the risk/reward for a 90-day swing trade is not sufficiently favorable.
?May 16, 9:00 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a large-cap, defensive healthcare services company with stable recurring revenue from laboratory testing — no recent SEC filings or news headlines suggest fundamental deterioration, so the 11% pullback from the 30-day high appears to reflect broad macro pressure rather than company-specific issues. The elevated 5-year breakeven inflation rate (2.7%, 2.5σ above trend) signals a risk-off rotation into inflation-hedged assets and away from stable-growth defensives, which could explain near-term multiple compression. However, with no confirming catalyst for the drop and DGX's historically resilient earnings profile, a partial mean-reversion toward the prior high over 90 days is plausible but not highly probable given the macro headwind.
?May 16, 8:58 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
?May 15, 6:37 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
?May 15, 6:33 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
?May 15, 6:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
?May 15, 6:15 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
?May 15, 3:38 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
?May 15, 9:18 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is down 1.52% with 387 minutes remaining — a modest but real move with ample time left in the session. The move is below the 2-5% threshold that would signal high conviction institutional flow, so it reads more as routine selling pressure than a decisive directional break. No news catalysts are present to explain or amplify the move, which is neutral rather than disqualifying. The macro context (5Y inflation expectations 2.5σ above trend) is modestly negative for rate-sensitive healthcare names like DGX insofar as elevated inflation expectations can pressure multiple expansion, but DGX is not a primary reactor to TIPS/gold/energy dynamics — so macro provides only weak incremental support for continuation. With no reversal signals evident and time still ample, there is no strong reason to fade the current direction. Assigning the floor continuation probability of 0.5 — momentum is present but not compelling enough to rate higher without volume confirmation or a cleaner macro/news catalyst.
?May 15, 9:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is down 1.52% with no attributable news catalyst, placing this in the ordinary momentum category. The move is meaningful but below the 2-5% threshold that would signal strong conviction flow. With 404 minutes remaining (essentially a full trading day still ahead from mid-morning), there is ample time for continuation, but also ample time for mean reversion. The macro context (elevated 5Y breakeven inflation at 2.5σ above trend) is not directly relevant to DGX, a healthcare/diagnostics name — DGX is not in Gold, Energy, or TIPS sectors, so macro context neither supports nor undermines the move. No headlines to explain the selloff, which is common and not disqualifying. With no reversal signals noted, no thin volume warning, and time remaining supportive of continuation, the base case is weak continuation momentum. Assigning 0.50 — the minimum threshold — reflecting the absence of both a strong continuation signal and a strong reversal signal. The bounded risk profile (1.5% stop, 3% target) justifies taking this borderline read at exactly the cutoff.
✓May 14, 9:36 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
DGX (Quest Diagnostics) is a defensively positioned, cash-generative healthcare services company with a durable business model built on recurring lab testing demand. The 10.4% pullback from its 30-day high occurs against a broadly constructive market backdrop today (SPY +0.79%, VXX -2.54%), suggesting the decline is likely idiosyncratic rather than macro-driven, though the absence of recent news or filings makes it difficult to pinpoint a catalyst. The elevated 5-year inflation expectations (T5YIE at 2.5σ above trend) could weigh on multiple expansion for defensive healthcare names, but DGX's pricing power and contract structures partially insulate it.
✓May 14, 9:35 PMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
DGX (Quest Diagnostics) is a well-established, defensive healthcare services company with stable cash flows and no recent negative filings or headlines to explain the 10.4% drop from its 30-day high, suggesting the move may be technically driven or linked to broader sector rotation rather than fundamental deterioration. The broad market tone today is constructively positive (SPY +0.79%, VXX -2.54%), which means the idiosyncratic weakness in DGX is notable but not panic-driven, and the lack of confirming negative news raises the probability of mean reversion. The elevated 5-year inflation expectations (T5YIE at 2.5σ above trend) are a mild headwind for valuation multiples but do not directly impair a diagnostics business model.
?May 14, 9:34 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a defensively positioned healthcare services company with stable recurring revenue from diagnostic testing, manageable debt, and consistent free cash flow generation — no recent filings or headlines indicate fundamental deterioration. The 10.4% drawdown from the 30-day high appears attributable to macro rotation rather than company-specific issues, potentially driven by rising inflation expectations (T5YIE at 2.7, 2.5σ above trend) pressuring rate-sensitive, lower-growth defensive equities and prompting rotation into inflation-benefiting sectors. However, the absence of any recent news or filings creates meaningful informational uncertainty about whether a catalyst for recovery exists within the 90-day window.
?May 14, 9:34 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
?May 14, 9:33 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a defensively positioned healthcare services company with stable recurring revenue from diagnostic testing, manageable debt, and consistent free cash flow generation — no recent filings or headlines indicate fundamental deterioration. The 10.4% drawdown from the 30-day high appears attributable to macro rotation rather than company-specific issues, potentially driven by rising inflation expectations (T5YIE at 2.7, 2.5σ above trend) pressuring rate-sensitive, lower-growth defensive equities and prompting rotation into inflation-benefiting sectors. However, the absence of any recent news or filings creates meaningful informational uncertainty about whether a catalyst for recovery exists within the 90-day window.
?May 14, 9:33 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
?May 14, 9:26 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
DGX (Quest Diagnostics) is a defensively positioned healthcare services company with stable recurring revenue from diagnostic testing, manageable debt, and consistent free cash flow generation — no recent filings or headlines indicate fundamental deterioration. The 10.4% drawdown from the 30-day high appears attributable to macro rotation rather than company-specific issues, potentially driven by rising inflation expectations (T5YIE at 2.7, 2.5σ above trend) pressuring rate-sensitive, lower-growth defensive equities and prompting rotation into inflation-benefiting sectors. However, the absence of any recent news or filings creates meaningful informational uncertainty about whether a catalyst for recovery exists within the 90-day window.
?May 14, 9:24 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
DGX (Quest Diagnostics) is a well-established, cash-generative healthcare diagnostics company with a defensible business model and no visible news or filing-based catalysts explaining the 10.4% decline from its 30-day high. The broad market is broadly positive today (SPY +0.79%, QQQ +0.71%), which means the drawdown appears idiosyncratic rather than macro-driven — a red flag suggesting company-specific stress, possibly from earnings guidance, pricing pressure, or volume headwinds that are not yet visible in available data. The elevated T5YIE (2.7, 2.5σ above trend) signals inflation expectations are rising, which could pressure DGX's cost structure and compress multiples for mid-cap healthcare service names.
?May 14, 2:03 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
DGX is down 1.36% today, which is a moderate but not dramatic move. The absence of any news catalyst makes it harder to assess whether real conviction is behind this sell-off or whether it's noise/light selling pressure. The macro context (elevated 5Y inflation breakevens at 2.5σ above trend) is most relevant to Gold, Energy, and TIPS sectors — not directly to DGX (Quest Diagnostics, a healthcare/diagnostics company), so macro provides no meaningful tailwind or headwind for continuation. With 102 minutes remaining, there is ample time for a move in either direction, but the lack of a clear catalyst and the modest magnitude (-1.36%, well below the 2-5% threshold that signals strong conviction flow) suggests this could easily fade or reverse into the close as intraday sellers cover. No reversal pattern is confirmed yet, but the setup does not present strong continuation pressure. Marginally below the 0.5 threshold — not taking the trade.

← Back to dashboard